Ipamorelin 10mg Peptide

Ipamorelin is a short peptide sequence that binds the ghrelin, or growth hormone secretagogue, receptor. It is among the most selective growth hormone (GH) secretagogues known: laboratory studies record no effect at all on ACTH, prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone or cortisol release[1]. That degree of specificity is why it draws research interest on two fronts, as a therapeutic in its own right and as a model peptide for working out how selectivity in receptor binding is achieved.

Ipamorelin is a synthetic pentapeptide agonist at the growth hormone secretagogue receptor type 1a, the receptor whose endogenous ligand is ghrelin. It is not a growth hormone releasing hormone analogue and does not act at the GHRH receptor, which is the distinction that separates it from sermorelin, tesamorelin and the CJC-1295 family. The two receptor systems converge on the somatotroph but arrive by different routes.

The property that defined it on introduction was selectivity. The paper describing it characterised ipamorelin as the first selective growth hormone secretagogue: it released growth hormone with potency comparable to earlier secretagogues of the GHRP series, but without the accompanying release of adrenocorticotropic hormone and cortisol that those compounds produced. Earlier growth hormone secretagogues raised several pituitary axes at once, and separating growth hormone release from the corticotropic response was the advance.

Mechanistically, receptor activation on the pituitary somatotroph signals through Gq and phospholipase C, raising intracellular calcium and triggering release of stored growth hormone. Because the mechanism acts on release of an existing pool and works alongside endogenous GHRH tone rather than replacing it, the resulting secretion retains a pulsatile character rather than producing a sustained elevation.

Glucocorticoids are the class of corticosteroids used to treat inflammation across conditions ranging from cancer to autoimmune disease, and they carry a host of serious side effects that frequently limits how useful they can be. Blunting those side effects would allow higher doses and longer courses, each of which could have positive benefits on morbidity and mortality. Several studies show ipamorelin reducing, and in some cases reversing, the side effects of glucocorticoid use.

Loss of bone density, and the fracture risk that follows it, is among the most profound problems associated with long-term glucocorticoid use. The current answers are bisphosphonates, hormone therapies and the newer monoclonal antibodies; each is an effective treatment in its own right, and each comes with side effects, limited efficacy or high cost. Ipamorelin, by contrast, is relatively inexpensive to produce and carries a very limited number of side effects.

Studies in rats show it stopping corticosteroid-driven bone loss altogether, and producing a four-fold increase in bone formation in animals exposed to those drugs[2]. Further studies find it raising bone mineral density systemically, which increases the strength of existing bone and newly formed bone alike[3]. It also offsets some of the other side effects of steroids along the way, muscle wasting and increased visceral fat deposition among them.

There is evidence to suggest that GH, and growth hormone secretagogues such as ipamorelin, reduce the catabolic effects glucocorticoids have on muscle. Rats given glucocorticoids showed a decrease in nitrogen wasting in the liver and improved nitrogen balance once ipamorelin was administered[4]. Muscle wasting is one of the primary side effects of glucocorticoid use and a common reason treatment has to stop, so countering muscle catabolism and bone-density loss with a single drug could be hugely beneficial to patients who require glucocorticoids.

Research in diabetic rats has revealed that ipamorelin can potentiate insulin release. The most likely route is indirect stimulation of the calcium channel found on the pancreatic islet cells where insulin is made and stored[5]. What the peptide does to the pancreas may sharpen understanding of the functional limitations of type 2 diabetes and lead toward novel therapeutics or even preventative measures.

Post-operative ileus (POI) is a common condition that follows certain types of surgery, and it is particularly common after abdominal procedures. The GI system ceases to function and the patient cannot take oral nutrition as a result. Pain can be part of the picture, but the primary problem with POI is that it slows discharge from hospital and lengthens overall recovery time.

Ipamorelin has been investigated in several proof-of-concept clinical trials to determine whether administering it can reduce POI. The research suggests that it does shorten time to first meal, by approximately 12 hours[6], [7].

Ipamorelin is a selective ghrelin receptor agonist and binds strongly to that receptor. The ghrelin receptor is known to increase in abundance in certain types of cancer, human carcinomas among them, and in heart failure. Putting those facts together, researchers recently speculated that ipamorelin could be used as a probe in positron emission tomography (PET) as an aid to diagnosis.

Basic in vitro studies have demonstrated the feasibility of that approach and have confirmed that ipamorelin[8], which is easy to synthesize in a lab, could theoretically be used as a PET probe.

Growth hormone release from the pituitary somatotroph is controlled by at least two separate receptor systems. The GHRH receptor responds to growth hormone releasing hormone from the hypothalamus. The growth hormone secretagogue receptor responds to ghrelin. Both converge on release of growth hormone, but they are pharmacologically distinct targets.

Ipamorelin acts only at the second. Sermorelin, tesamorelin and the CJC-1295 family act at the first. This is why the two classes are frequently discussed together and why combining them is common in the literature: they are not redundant, because they engage different receptors on the same cell.

It also means results from one class should not be read across to the other. A finding about a GHRH analogue is not evidence about a secretagogue, and the two differ in their dependence on intact endogenous signalling.

The earlier growth hormone releasing peptides, GHRP-6 and GHRP-2, raised growth hormone but also raised adrenocorticotropic hormone, cortisol and prolactin. That lack of specificity limited their usefulness as tools, because any observed effect could be attributed to several simultaneously altered axes.

Ipamorelin was characterised as producing comparable growth hormone release without those accompanying rises. That is what the word selective denotes in its original description, and it is a claim about specificity across pituitary axes rather than about receptor subtype selectivity in the usual pharmacological sense.

For laboratory work this matters directly: it is the property that makes ipamorelin a cleaner probe of growth hormone secretion than the compounds that preceded it.

Ipamorelin has no marketing authorisation in any jurisdiction. It was investigated clinically, including for postoperative gastrointestinal indications, and did not progress to approval. There are no adequately powered, replicated human efficacy trials supporting the musculoskeletal or body composition uses most often discussed for it.

Recent structured reviews of peptides in sports medicine and orthopaedics reach the same conclusion consistently, and note in addition that it appears on prohibited lists in competitive sport. Material supplied for research is for in-vitro laboratory use only and is not a medicine.

Ipamorelin contains three non-proteinogenic residues: alpha-aminoisobutyric acid at position one, D-2-naphthylalanine and D-phenylalanine. Those substitutions are deliberate, conferring protease resistance and receptor selectivity, and they also mean that standard enzymatic sequencing approaches behave unusually on this molecule.

The C-terminal amide is part of the specification. A free-acid version has a mass one dalton higher and is a different molecule, so the reported mass on a certificate distinguishes the intended product from a common synthesis-related variant.